Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Fixed- Dose Study Evaluating the Effect of One Dose of Rimonabant (20 mg/day) on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled with Insulin
To assess the effect of rimonabant on HbA1c in patients with type 2 diabetes treated with insulin.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TCD6511 : Essai de phase 1-2, en escalade de dose évaluant l’association d’une nouvelle taxane (XRP9881) et capécitabine chez des patientes ayant un cancer du sein métastatique. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
A Dose-Escalating, Multicenter, Single Arm, Open-Label Study of XRP9881 in Combination With Capecitabine (Xeloda), in Metastatic Breast Cancer Patients With Disease Progressing After Anthracycline and...
Country
France
organs
Sein
Specialty
Chimiothérapie
Essai clos aux inclusions
More information
Woman Max 99 years
Sanofi-Synthelabo Recherche, a subsidiary of sanofi-aventis group
Update Il y a 4 ans
A Multicenter, Open-Label, Single-Arm Study of Intravenous AVE0005 VEGF Trap Administered Every 2 Weeks in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites
Estimate the repeat paracentesis response rate RPRR in advanced ovarian cancer patients with recurrent symptomatic malignant ascites
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Aventis Groupe
Update Il y a 4 ans
A RANDOMIZED, DOUBLE BLIND, TWO ARM, PARALLEL, PLACEBO CONTROLLED STUDY OF RIMONABANT 20MG EFFECT ON HIGH DENSITY LIPOPROTEIN KINETICS IN PATIENTS WITH ABDOMINAL OBESITY AND ADDITIONAL CARDIOMETABOLIC RISK FACTORS
The Primary End-point is the fractional catabolic rate of ApoA-I in HDL after 12 months of treatment.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur MSD
Update Il y a 4 ans
An open, randomised, comparative, multicentre study of the immunogenicity and safety of concomitant versus separate administration of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) and a booster dose of Infanrix® hexa in healthy children 12 to 23 months of age
To demonstrate that ProQuad® can be administered concomitantly with a booster dose of Infanrix® hexa to healthy children 12 to 23 months of age without impairing neither the antibody response rates to...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
AFEQT : Essai de phase 3 évaluant la tolérance de l’aflibercept associé à une chimiothérapie de type FOLFIRI comprenant de l’irinotécan, du 5-fluorouracile et de la dl-Leucovorine, chez des patients ayant un cancer colorectal métastatique après une première ligne de chimiothérapie à base d’oxaliplatine. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer la tolérance d’une thérapie ciblée, l’aflibercept, en association avec du FOLFIRI après une première ligne de chimiothérapie à base d’oxaliplatine, chez des patie...
Country
France
organs
Côlon ou Rectum (colorectal)
Specialty
Chimiothérapie
,
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur SA
Update Il y a 4 ans
Booster Effect and Safety of a DTaP-IPV-Hib Combined Vaccine, with or without Hep B, in Healthy Subjects 11 to 18 Months of Age Who Received a Hexavalent or Hexavalent/Pentavalent Combined Vaccine during the Primary Series Účinek a bezpečnost přeočkování kombinovanou vakcínou DTaP-IPV-Hib s podáním vakcíny proti hepatitidě B či bez ní u zdravých subjektů ve věku 11 až 18 měsíců, kteří během primární série obdržely hexavalentní nebo hexavalentní/pentavalentní kombinovanou vakcínu
Immunogenicity Groups 1 and 2 • Assess the antibody persistence of DTaP-IPV-HB-Hib or Infanrix hexa following a 3-dose primary series at 2, 3, and 4 months of age (MoA) before the administration of ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Safety and Immunogenicity of the Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Children Aged 3 to 8 Years
To demonstrate non-inferiority of antibody (Ab) responses induced by QIV compared with the TIV.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
Sanofi-Aventis TED6829 : Essai de phase 1 évaluant la tolérance et la pharmacocinétique d’un anticorps anti-CD19 (SAR3419), chez des patients ayant un lymphome à cellules B CD19+. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la plus adaptée d’un traitement par un anticorps anti-CD19 (SAR3419), chez des patients ayant un lymphome à cellules B CD19+. Les patients recevront ...
Country
France
organs
Lymphomes non hodgkinien
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi Pasteur
Update Il y a 4 ans
Immunogenicity and Safety of the Trivalent Influenza Vaccine (Split-Virion, Inactivated), Northern Hemisphere 2013-2014 Formulation (Intradermal Route)
To evaluate the compliance, in terms of immunogenicity, of the ID influenza vaccine NH 2013-2014 formulation with the requirements of the Committee for Medicinal Products for Human Use (CHMP) Note f...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
5
6
7
8
9
10
11
12
13
14
Next